SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending as investors anticipate upcoming earnings and potential hyperscaler announcements, crucial for the company's AI infrastructure growth. Community discussions revolve around the timing of a new lease and the impact of Macquarie's recent funding draw. Bullish sentiment remains high due to the expected increase in AI data center demand and APLD's strategic position.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ (LAES) is trending due to a strategic partnership to develop 'Made in US' post-quantum cryptography solutions for US government and defense, sparking bullish sentiment. The community is actively discussing the potential for a short squeeze and significant upside, drawing comparisons to other quantum stocks. With high trading volume and positive news, investors are optimistic about the company's future growth and potential double-digit price targets.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending due to recent AI partnerships, sparking investor excitement about its potential in the agentic AI space; some view it as undervalued compared to competitors like $PLTR. The community is discussing its strategic shift from RPA to AI-driven automation and whether it can sustain growth, while others are eyeing potential short squeezes.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is trending as gold prices surge to new all-time highs, driven by safe-haven demand amid economic uncertainty and geopolitical tensions, potentially signaling a broader market correction. Community members are actively debating whether this rally is sustainable, with some pointing to overbought conditions while others anticipate further gains due to ongoing global instability and central bank activity. Discussions also revolve around the relationship between gold, the dollar, and other asset classes like equities and crypto.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices surge, nearing multi-decade highs, fueled by potential for a short squeeze and discussions of a 45-year cup and handle formation. Community chatter revolves around big banks potentially manipulating the price and excitement about silver's potential to reach new all-time highs. Some investors are adding to their positions, while others are taking profits or expressing concerns about a possible pullback.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security Solutions is trending amid discussions about defense spending, potential contract wins, and comparisons to other high-growth tech and defense companies. The community is actively debating its valuation, potential for acquisitions, and upcoming catalysts like government contracts and drone technology advancements. Some traders are taking profits after a significant run-up, while others see it as a long-term growth play.

Global Health Solutions Inc is an American company that works with partners to eliminate diseases that have plagued humanity for centuries and protect the health of populations by helping countries build strong health systems. The private company is located in the US. The company brings together key stakeholders around the world with a common goal to stop diseases and strengthen health systems through powerful partnerships. The company consists of programs and focus areas that cover a range of health issues including neglected tropical diseases, infectious diseases, vaccines, field epidemiology, public health informatics, health workforce development, and health ethics. The company's end goal is to eliminate diseases and protect the health of populations.

Turn Therapeutics Inc.

Turn Therapeutics Inc

Turn Therapeutics ($TTRX) is trending due to significant price volatility following its recent IPO, with the community actively debating potential short squeezes and bag holding scenarios. Discussions revolve around the stock's rapid price fluctuations and whether it represents a genuine opportunity or a classic pump-and-dump scheme. The stock's performance is also drawing comparisons to other recent high-flying biotech stocks.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending due to its expanding partnerships in the autonomous delivery space, particularly with DoorDash, sparking discussions about the company's growth potential and market dominance. Community members are actively discussing the high call option volume, potential for a short squeeze, and the long-term prospects of robotic food delivery. Despite some concerns about high operating costs, the stock is seeing increased attention as a strong relative strength name in the robotics sector.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy ($ENPH) is trending as the stock shows signs of bouncing back, prompting discussions about a potential breakout and short squeeze. Community members are actively debating whether the stock has hit its rock bottom and if it's poised for a significant upward move, while also noting positive momentum in the broader solar sector. Some analysts point to potential benefits from future interest rate cuts, even amidst concerns about policy headwinds.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amid discussions around its valuation, potential for a short squeeze, and a recent healthcare partnership with OneMedNet; the community is debating whether the stock is overvalued and if it can sustain its high growth, while some point to the potential for breakout traders to drive the price higher. Bullish sentiment remains strong despite some concerns about the company's valuation and the sustainability of its growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of InMed Pharmaceuticals surged to levels not seen in nearly five months, capturing significant attention from retail investors.&nbsp;The biopharma company, with a market cap of just under $4 million, announced on Tuesday that its INM-901 small molecule drug candidate for Alzheimer's disease demonstrated promising results in a recent clinical trial.The study showed that INM-901 significantly reduced several markers of neuroinflammation, both in plasma and the brain.&nbsp;Specifically, the high-dose treated group exhibited a dose-dependent reduction in pro-inflammatory cytokines and neurofilament light chain levels in the plasma.&nbsp;Additionally, the trial indicated a reduction in key neuroinflammatory genes in the brain, signaling a potential breakthrough in Alzheimer's treatment.Eric Hsu, InMed's Senior Vice President of Preclinical R&amp;D, expressed excitement over the results, noting, "The ability of INM-901 to actively reduce inflammation is an exciting development, as neuroinflammation has emerged as a promising new drug target beyond existing AD treatments focused primarily on removing amyloid beta plaques and tau protein tangles."&nbsp;He added, "INM-901 may address multiple pathological factors, making it a very promising drug candidate."The positive trial results propelled InMed into the top 25 trending stocks on Stocktwits, with a flood of bullish comments on the platform.&nbsp;One user expressed happiness with the stock's surge and speculated on the potential for a buy-out.<stembedurl>https://stocktwits.com/pennyman/message/600871159</stembedurl>Another suggested that InMed's current levels were too good an entry point to miss.<stembedurl>https://stocktwits.com/AmbushPredator/message/600878277</stembedurl>According to Koyfin data, InMed has only about 718,000 shares outstanding and a short interest of 1.3%.&nbsp;While <a href="https://stocktwits.com/symbol/INM">InMed's stock</a> is down nearly 30% over the past 12 months, it has gained approximately 14% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Nano-Cap InMed Ignites Retail Frenzy As Stock Soars After Alzheimer's Drug Trial Shows Promise

The positive trial results propelled InMed into the top 25 trending stocks on Stocktwits, with a flood of bullish comments on the platform. 

Equity

The positive trial results propelled InMed into the top 25 trending stocks on Stocktwits, with a flood of bullish comments on the platform. 


EXCLUSIVE: New Alzheimer's Treatment? Promising Cannabinoid Compound Shows Hope, InMed CEO Says

InMed Pharmaceuticals is making strides in Alzheimer's research with its development of a cannabinoid-based compound.
read more...

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling pathwayIn Vivo studies demonstrate INM-901 reduces neuroinflammation and improves...

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ('InMed' or the 'Company'), a leader in the manufacturing, development and commercialization...

InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying

The Dow Jones index closed higher by over 450 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

Advancing two new preclinical programs in Alzheimer's and Age-Related Macular DegenerationClosed calendar year 2023 with cash position of US$9.5 million164% revenue growth in the commercial BayMedica...

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

Vancouver, British Columbia--(Newsfile Corp. - February 9, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ('InMed' or the 'Company'), a leader in the manufacturing, development and...

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

Vancouver, British Columbia--(Newsfile Corp. - January 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ('InMed' or the 'Company'), a leader in the manufacturing, development and...

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

Advancing INM-901 as a multimodal treatment option for Alzheimer's DiseaseAdvancing INM-089 in the treatment of Age-related Macular DegenerationActively seeking partnerships to advance INM-755 in...

InMed Pharmaceuticals, Inc. engages in developing small molecule drug candidates targeting the CB1/CB2 receptors. It operates through the InMed Pharma and BayMedica Commercial segments. The InMed Pharma segment focuses on research and development. The BayMedica Commercial segment refers to manufacturing technologies to produce and commercialize bulk cannabinoids for sale as ingredients in the health and wellness industry. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.

InMed Pharmaceuticals Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

INM
InMed Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest INM News

INM InMed Pharmaceuticals Inc